Elicera Therapeutics receives Notice of Allowance for Chinease patent protecting the iTANK platform

Gothenburg, September 8, 2023 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company’s commercially available platform iTANK, today announced that it has received a so called “Notice of Allowance” from the Chinease Patent Office in its patent application relating to the use of the iTANK-technology in CAR T-cell therapies.

Once granted, the patent can be kept in force until 2036.

"iTANK is one of our key assets and together with the recently approved European patent we now have strong protection for the technology. China is one of the most important markets in the CAR T-cell field so this is very significant for us," says Jamal El-Mosleh , CEO of Elicera Therapeutics.